Cellular mechanisms underlying the interaction between cannabinoid and opioid system

Current Drug Targets

Volumn 11, Issue 4, 2010, Pages 393-405

  Parolaro, D ^a,b   Rubino, T ^a   Vigano D ^a,b   Massi, P ^c   Guidali, C ^a   Realini, N ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Zardi Gori Foundation   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Addiction; Cannabinoids; Cognition; Emotion; Immunity; Interaction; Opioids; Pain

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; MORPHINE; NALOXONE; NOLADIN ETHER; NORBINALTORPHIMINE; OPIATE; RIMONABANT; U 50887; UNCLASSIFIED DRUG;

ANALGESIA; ANTINOCICEPTION; CENTRAL NERVOUS SYSTEM; COGNITION; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG MECHANISM; EMOTIONALITY; HUMAN; NEUROPATHIC PAIN; NONHUMAN; PAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; BRAIN; CANNABINOIDS; COGNITION; DRUG INTERACTIONS; EMOTIONS; ENDOCANNABINOIDS; HUMANS; IMMUNE SYSTEM; OPIOID PEPTIDES; OPIOID-RELATED DISORDERS; PAIN; RECEPTOR CROSS-TALK; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID; REWARD; SIGNAL TRANSDUCTION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77950840678     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790980367     Document Type: Review

References (177)

1. Wang Y, Van Bockstaele EJ, Liu-Chen LY. In vivo trafficking of endogenous opioid receptors. Life Sci 2008; 83(21-22): 693-699
2. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008; 20 (Suppl 1): 10-14 (Pubitemid 351552670)
3. Childers SR. Opioid receptor-coupled second messenger systems. Life Sci 1991; 48(21): 1991-2003.
4. Childers SR, Fleming L, Konkoy C, Marckel D, Pacheco M, Sexton T, Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann NY Acad Sci 1992; 28: 654: 33-51.
5. Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995; 35: 607-634
6. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18(1): 22-29
7. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2000; 22(11): 565-572 (Pubitemid 33042646)
8. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci 1988; 11(7): 308-314
9. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11(2): 563-583
10. Mailleux P, Vanderhaeghen JJ. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Lett 1992; 148(1-2): 173-176
11. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 2001; 21(3): 823-833 (Pubitemid 32163123)
12. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 1996; 276(2): 585-593 (Pubitemid 126660496)
13. Fernández-Ruiz JJ, Muñoz RM, Romero J, Villanua MA, Makriyannis A, Ramos JA. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochem Pharmacol 1997; 53(12): 1919-1927 (Pubitemid 27356065)
14. Romero J, Wenger T, de Miguel R, Ramos JA, Fernández-Ruiz JJ. Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation. Life Sci 1998; 63(5): 351-356 (Pubitemid 28335633)
15. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992; 262(1): 10-18
16. Hohmann AG, Briley EM, Herkenham M.Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999; 822(1-2): 17-25. (Pubitemid 29222825)
17. Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 2001; 12(17): 3689-3692 (Pubitemid 33105152)
18. Rios C, Gomes I, Devi LA. Mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 2006; 148(4): 387-395 (Pubitemid 43882074)
19. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, et al. Mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 2008; 108(3): 308-319
20. Viganò D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 2005; 81(2): 360-368 (Pubitemid 40807133)
21. Fattore L, Deiana S, Spano SM, Cossu G, Fadda P, Scherma M, et al. Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav 2005; 81(2): 343-359 (Pubitemid 40807132)
22. Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 1988; 36(2-3): 189-261.
23. Bhargava HN, Ramarao P. The effect of Panax ginseng on the development of tolerance to the pharmacological actions of morphine in the rat. Gen Pharmacol 1991; 22(3): 521-525
24. Rubino T, Tizzoni L, Viganò D, Massi P, Parolaro D. Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport 1997; 8(15): 3219-3223 (Pubitemid 27461370)
25. Tsou K, Patrick SL, Walker JM. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 1995; 280(3): R13-5.
26. Aceto MD, Scates SM, Lowe JA, Martin BR. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996; 278(3): 1290-1295
27. Rubino T, Patrini G, Massi P, Fuzio D, Viganò D, Giagnoni G, et al. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998; 285(2): 813-819 (Pubitemid 28237466)
28. Welch SP. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J Pharmacol Exp Ther 1993; 265(2): 633-640
29. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999; 848(1-2): 183-190 (Pubitemid 30001667)
30. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74(11): 1317-1324
31. Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, et al. The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 2001; 94(5): 882-887 (Pubitemid 32429761)
32. Frederickson RC, Hewes CR, Aiken JW. Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism by l-(-)-delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 1976; 199(2): 375-384
33. Basilico L, Parolaro D, Colleoni M, Costa B, Giagnoni G. Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus. Eur J Pharmacol 1999; 376(3): 265-271 (Pubitemid 29320152)
34. Kulkarni-Narla A, Brown DR. Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons. Neurosci Lett 2001; 308(3): 153-156 (Pubitemid 32710147)
35. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999; 384(1): 37-42.
36. Izzo AA, Mascolo N, Tonini M, Capasso F. Modulation of peristalsis by cannabinoid CB(1) ligands in the isolated guinea-pig ileum. Br J Pharmacol 2000; 129(5): 984-990
37. Massi P, Vaccani A, Romorini S, Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuroimmunol 2001; 117(1-2): 116-124 (Pubitemid 32595499)
38. Massi P, Vaccani A, Rubino T, Parolaro D. Cannabinoids and opioids share cAMP pathway in rat splenocytes. J Neuroimmunol 2003; 145(1-2): 46-54. (Pubitemid 37485967)
39. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 2002; 163(1): 111-117
40. Gavériaux-Ruff C, Kieffer BL. Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 2002; 36(2-3): 62-71.
41. Marín S, Marco E, Biscaia M, Fernández B, Rubio M, Guaza C, Schmidhammer H, Viveros MP. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol Biochem Behav 2003; 74(3): 649-656 (Pubitemid 36126543)
42. Corchero J, Fuentes JA, Manzanares J. Chronic treatment with CP-55,940 regulates corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat. Life Sci 1999; 64(11): 905-911
43. Valverde O, Ledent C, Beslot F, Parmentier M, Roques BP. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 2000; 12(2): 533-539
44. Costanzi M, Battaglia M, Populin R, Cestari V, Castellano C. Anandamide and memory in CD1 mice: effects of immobilization stress and of prior experience. Neurobiol Learn Mem 2003; 79(3): 204-211
45. Poncelet M, Barnouin MC, Brelière JC, Le Fur G, Soubrié P. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berl) 1999; 144(2): 144-150
46. Ayhan IH, Kaymakçalan S, Tulunay FC. Interaction between delta 9-tetrahydrocannabinol and morphine on the motor activity of mice. Psychopharmacology (Berl) 1979; 63(2): 169-172
47. Ulkü E, Ayhan IH, Tulunay FC, Uran B, Kaymakçalan S. Effect of delta 9-tetrahydrocannabinol on the morphine-induced hyperactivity of mice. Psychopharmacology (Berl) 1980; 69(2): 201-205
48. Tulunay FC, Ayhan IH, Sparber SB. The effects of morphine and delta-9-tetrahydrocannabinol on motor activity in rats. Psychopharmacology (Berl) 1982; 78(4): 358-360
49. Buttarelli FR, Pontieri FE, Margotta V, Palladini G. Cannabinoid-induced stimulation of motor activity in planaria through an opioid receptor-mediated mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(1): 65-68
50. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008; 160: 1-24.
51. Bodnar RJ. Endogenous opiates and behavior: 2006. Peptides 2007; 28(12): 2435-2513
52. Robledo P, Berrendero F, Ozaita A, Maldonado R. Advances in the field of cannabinoid - opioid cross-talk. Addict Biol 2008; 13(2): 213-224
53. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994; 270(1): 219-227
54. Houser SJ, Eads M, Embrey JP, Welch SP. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. Brain Res 2000; 857(1-2): 337-342
55. Pugh G Jr, Mason DJ Jr, Combs V, Welch SP. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther 1997; 281(2): 730-737
56. Mason DJ Jr, Lowe J, Welch SP. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Eur J Pharmacol 1999; 378(3): 237-248
57. Rowen DW, Embrey JP, Moore CH, Welch SP. Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance. Pharmacol Biochem Behav 1998; 59(2): 399-404.
58. Haller VL, Stevens DL, Welch SP. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Eur J Pharmacol 2008; 600(1-3): 50-58
59. Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002; 96(3): 253-260
60. Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 2003; 3(1): 62-67
61. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003; 100(18): 10529-10533
62. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 2005; 102(8): 3093-3098
63. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, et al. CB2 cannabinoid receptor mediation of antinociception. Pain 2006; 122(1-2): 36-42.
64. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394(6690): 277-281
65. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76(1-2): 189-199
66. Farquhar-Smith WP, Rice AS. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 2001; 94(3): 507-513
67. Farquhar-Smith WP, Jaggar SI, Rice AS. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 2002; 97(1-2): 11-21.
68. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001; 93(3): 239-245
69. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005; 48(5): 658-672
70. Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 2004; 20(9): 2311-2320
71. Jhaveri MD, Sagar DR, Elmes SJ, Kendall DA, Chapman V.Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007; 36(1): 26-35.
72. Páldyová E, Bereczki E, Sántha M, Wenger T, Borsodi A, Benyhe S. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. Acta Biol Hung 2007; 58 (Suppl): 113-129
73. Páldyová E, Bereczki E, Sántha M, Wenger T, Borsodi A, Benyhe S. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochem Int 2008; 52(1-2): 321-328
74. Páldy E, Bereczki E, Sántha M, Wenger T, Borsodi A, Zimmer A, Benyhe S. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. Neurochem Int 2008; 53(6-8): 309-316
75. Milligan G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discov Today 2006; 11(11-12): 541-549
76. Thorat SN, Bhargava HN. Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol 1994; 260(1): 5-13.
77. Viganò D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C, et al. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) 2005; 182(4): 527-536
78. Romero J, Fernández-Ruiz JJ, Vela G, Ruiz-Gayo M, Fuentes JA, Ramos JA. Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice. Drug Alcohol Depend 1998; 50(3): 241-249
79. Gonzalez S, Fernandez-Ruiz J, Sparpaglione V, Parolaro D, Ramos JA. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend 2002; 66(1): 77-84.
80. Smith FL, Cichewicz D, Martin ZL, Welch SP. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 60(2): 559-566
81. Cichewicz DL, Martin ZL, Smith FL, Welch SP. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 1999; 289(2): 859-867
82. Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 2003; 304(3): 1010-1015
83. Cichewicz DL, Haller VL, Welch SP. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine. J Pharmacol Exp Ther 2001; 297(1): 121-127
84. Smith PA, Selley DE, Sim-Selley LJ, Welch SP. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 2007; 571(2-3): 129-137
85. Lim G, Wang S, Mao J. Central glucocorticoid receptors modulate the expression of spinal cannabinoid receptors induced by chronic morphine exposure. Brain Res 2005; 1059(1): 20-27 (Pubitemid 41457322)
86. Bouaboula M, Poinot-Chazel C, Bourrié B, Canat X, Calandra B, Rinaldi-Carmona M, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995; 312 ( Pt 2): 637-641
87. Fukuda K, Kato S, Morikawa H, Shoda T, Mori K. Functional coupling of the delta-, mu-, and kappa-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells. J Neurochem 1996; 67(3): 1309-1316
88. Cannich A, Wotjak CT, Kamprath K, Hermann H, Lutz B, Marsicano G. CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learn Mem 2004; 11(5): 625-632
89. Butler RK, Rea K, Lang Y, Gavin AM, Finn DP. Endocannabinoid-mediated enhancement of fear-conditioned analgesia in rats: opioid receptor dependency and molecular correlates. Pain 2008; 140(3): 491-500.
90. Ménard DP, van Rossum D, Kar S, Quirion R. Alteration of calcitonin gene related peptide and its receptor binding sites during the development of tolerance to mu and delta opioids. Can J Physiol Pharmacol 1995; 73(7): 1089-1095
91. Menard DP, van Rossum D, Kar S, St Pierre S, Sutak M, Jhamandas K, et al. A calcitonin gene-related peptide recep-tor antagonist prevents the development of tolerance to spinal morphine analgesia. J Neurosci 1996; 16(7): 2342-2351
92. Powell KJ, Ma W, Sutak M, Doods H, Quirion R, Jhamandas K. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br J Pharmacol 2000; 131(5): 875-884
93. Powell KJ, Quirion R, Jhamandas K. Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Eur J Neurosci 2003; 18(6): 1572-1583
94. Trang T, Ma W, Chabot JG, Quirion R, Jhamandas K. Spinal modulation of calcitonin gene-related peptide by endocannabinoids in the development of opioid physical dependence. Pain 2006; 126(1-3): 256-271
95. Trang T, Sutak M, Jhamandas K. Involvement of cannabinoid (CB1)-receptors in the development and maintenance of opioid tolerance. Neuroscience 2007; 146(3): 1275-1288
96. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001; 133(4): 586-594
97. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001; 92(1-2): 91-100. (Pubitemid 32367940)
98. Pol O, Murtra P, Caracuel L, Valverde O, Puig MM, Maldonado R. Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain. Neuropharmacology 2006; 50(1): 123-132 (Pubitemid 43069778)
99. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111(1): 43-50.
100. Cabot PJ, Cramond T, Smith MT. Morphine has a dual concentration- dependent effect on K(+)-evoked substance P release from rat peripheral airways. Pulm Pharmacol Ther 1997; 10(4): 215-221 (Pubitemid 29094864)
101. Rittner HL, Brack A, Machelska H, Mousa SA, Bauer M, Schäfer M, Stein C. Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology 2001; 95(2): 500-508 (Pubitemid 32720742)
102. Kauser S, Schallreuter KU, Thody AJ, Gummer C, Tobin DJ. Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol 2003; 120(6): 1073-1080 (Pubitemid 36702920)
103. Cox ML, Welch SP. The antinociceptive effect of Delta9- tetrahydrocannabinol in the arthritic rat. Eur J Pharmacol 2004; 493(1-3): 65-74.
104. Williams J, Haller VL, Stevens DL, Welch SP. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9- tetrahydrocannabinoid-induced antinociception. Eur J Pharmacol 2008; 584(1): 78-86.
105. Manzanedo C, Aguilar MA, Rodríguez-Arias M, Navarro M, Miñarro J. Cannabinoid agonist-induced sensitisation to morphine place preference in mice. Neuroreport 2004; 15(8): 1373-1377 (Pubitemid 38757284)
106. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 2005; 30(11): 2046-2057 (Pubitemid 43093504)
107. Norwood CS, Cornish JL, Mallet PE, McGregor IS. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol 2003; 465(1-2): 105-114
108. Ellgren M, Spano SM, Hurd YL. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 2007; 32(3): 607-615 (Pubitemid 46271055)
109. Skoubis PD, Lam HA, Shoblock J, Narayanan S, Maidment NT. Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice. Eur J Neurosci 2005; 21(5): 1379-1384 (Pubitemid 40516636)
110. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci 2002; 22(9): 3312-3320
111. Koob GF. Neural mechanisms of drug reinforcement. Ann NY Acad Sci 1992; 654: 171-191
112. Biscaia M, Fernández B, Higuera-Matas A, Miguéns M, Viveros MP, García-Lecumberri C, Ambrosio E. Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55,940 on morphine self-administration behaviour and the endogenous opioid system. Neuropharmacology 2008; 54(5): 863-873
113. Jardinaud F, Roques BP, Noble F. Tolerance to the reinforcing effects of morphine in delta9-tetrahydrocannabinol treated mice. Behav Brain Res 2006; 173(2): 255-261 (Pubitemid 44291827)
114. Chaperon F, Thiébot MH. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999; 13(3): 243-281 (Pubitemid 30265251)
115. Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 2001; 104(4): 923-926
116. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001; 21(14): 5344-5350
117. Navarro M, Carrera MR, Del Arco I, Trigo JM, Koob GF, Rodríguez de Fonseca F. Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. Eur J Pharmacol 2004; 501(1-3): 235-237 (Pubitemid 39298957)
118. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 2003; 17(8): 1723-1726 (Pubitemid 36628140)
119. Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, et al. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 2001; 132(8): 1809-1816
120. Caillé S, Parsons LH. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci 2003; 18(11): 3145-3149 (Pubitemid 38021557)
121. De Vries TJ, Homberg JR, Binnekade R, Raasø H, Schoffelmeer AN. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berl) 2003; 168(1-2): 164-169 (Pubitemid 36851175)
122. Singh ME, Verty AN, McGregor IS, Mallet PE. A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Res 2004; 1026(2): 244-253
123. Parolaro D, Rubino T. The role of the endogenous cannabinoid system in drug addiction. Drug News Perspect 2008; 21(3): 149-157 (Pubitemid 351809138)
124. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 2003; 306(1): 93-102.
125. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000; 12(11): 4038-4046
126. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283(5400): 401-404
127. Cossu G, Ledent C, Fattore L, Imperato A, Böhme GA, Parmentier M, Fratta W. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001; 118(1): 61-65
128. Rice OV, Gordon N, Gifford AN. Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res 2002; 945(1): 135-138
129. Fattore L, Spano S, Cossu G, Deiana S, Fadda P, Fratta W. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 2005; 48(8): 1097-1104
130. Viganò D, Rubino T, Di Chiara G, Ascari I, Massi P, Parolaro D. Mu opioid receptor signaling in morphine sensitization. Neuroscience 2003; 117(4): 921-929
131. Fattore L, Fadda P, Fratta W. Endocannabinoid regulation of relapse mechanisms. Pharmacol Res 2007; 56(5): 418-427
132. Caillé S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 2007; 27(14): 3695-3702
133. Caillé S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 2006; 31(4): 804-813
134. Alvarez-Jaimes L, Polis I, Parsons LH. Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala. Neuropsychopharmacology 2008; 33(10): 2483-2493
135. Azizi P, Haghparast A, Hassanpour-Ezatti M. Effects of CB1 receptor antagonist within the nucleus accumbens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitized rats. Behav Brain Res 2009; 197(1): 119-124
136. Zarrindast MR, Nouri M, Ahmadi S. Cannabinoid CB1 receptors of the dorsal hippocampus are important for induction of conditioned place preference (CPP) but do not change morphine CPP. Brain Res 2007; 1163: 130-137
137. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997; 276(5321): 2048-2050
138. Caillé S, Parsons LH. Intravenous heroin self-administration decreases GABA efflux in the ventral pallidum: an in vivo microdialysis study in rats. Eur J Neurosci 2004; 20(2): 593-596
139. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 1990; 102(2): 156-162
140. Solinas M, Zangen A, Thiriet N, Goldberg SR. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. Eur J Neurosci 2004; 19(12): 3183-3192
141. Braida D, Iosuè S, Pegorini S, Sala M. Delta9- tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol 2004; 506(1): 63-69
142. Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl) 2004; 173(1-2): 186-194
143. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002; 22(3): 1146-1154
144. Castañé A, Robledo P, Matifas A, Kieffer BL, Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci 2003; 17(1): 155-159
145. Mendizábal V, Zimmer A, Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. Neuropsychopharmacology 2006; 31(9): 1957-1966
146. Allen KV, McGregor IS, Hunt GE, Singh ME, Mallet PE. Regional differences in naloxone modulation of Delta(9)-THC induced Fos expression in rat brain. Neuropharmacology 2003; 44(2): 264-274
147. Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, Fratta W. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br J Pharmacol 2004; 143(3): 343-350
148. Hine B, Torrelio M, Gershon S. Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC. Psychopharmacol Commun 1975; 1(3): 275-283
149. Deikel SM, Carder B. Attentuation of precipitated abstinence in methadone-dependent rats by delta9-THC. Psychopharmacol Commun 1976; 2(1): 61-65
150. Vela G, Ruiz-Gayo M, Fuentes JA. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 1995; 34(6): 665-668
151. Yamaguchi T, Hagiwara Y, Tanaka H, Sugiura T, Waku K, Shoyama Y, et al. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 2001; 909(1-2): 121-126
152. Del Arco I, Navarro M, Bilbao A, Ferrer B, Piomelli D, Rodríguez De Fonseca F. Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404. Eur J Pharmacol 2002; 454(1): 103-104
153. Lichtman AH, Sheikh SM, Loh HH, Martin BR. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 2001; 298(3): 1007-1014
154. Rubino T, Massi P, Viganò D, Fuzio D, Parolaro D. Long-term
155. Navarro M, Chowen J, Rocío A Carrera M, del Arco I, Villanúa MA, et al. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 1998; 9(15): 3397-3402
156. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther 2002 ; 95(2): 153-164
157. González S, Schmid PC, Fernández-Ruiz J, Krebsbach R, Schmid HH, Ramos JA. Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats. Addict Biol 2003; 8(2): 159-166
158. Romero J, Fernández-Ruiz JJ, Vela G, Ruiz-Gayo M, Fuentes JA, Ramos JA. Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice. Drug Alcohol Depend 1998; 50(3): 241-249
159. Kaymakçalan S, Ayhan IH, Tulunay FC. Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats. Psychopharmacology (Berl) 1977; 55(3): 243-249
160. Valverde O, Noble F, Beslot F, Daugé V, Fournié-Zaluski MC, Roques BP. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 2001; 13(9): 1816-1824
161. Corchero J, Oliva JM, García-Lecumberri C, Martin S, Ambrosio E, Manzanares J. Repeated administration with Delta9-tetrahydrocannabinol regulates mu-opioid receptor density in the rat brain. J Psychopharmacol 2004; 18(1): 54-58
162. Jardinaud F, Crété D, Canestrelli C, Ledent C, Roques BP, Noble F. CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited. Brain Res 2005; 1063(1): 77-83.
163. Zarrindast MR, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, Rezayof A. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system. Behav Pharmacol 2008; 19(7): 716-723
164. Valverde O, Maldonado R, Valjent E, Zimmer AM, Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 2000; 20(24): 9284-9289
165. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87(5): 1932-1936
166. Costanzi M, Battaglia M, Populin R, Cestari V, Castellano C. Anandamide and memory in CD1 mice: effects of immobilization stress and of prior experience. Neurobiol Learn Mem 2003; 79(3): 204-211
167. Costanzi M, Battaglia M, Rossi-Arnaud C, Cestari V, Castellano C. Effects of anandamide and morphine combinations on memory consolidation in cd1 mice: involvement of dopaminergic mechanisms. Neurobiol Learn Mem 2004; 81(2): 144-149
168. Hoffman AF, Lupica CR. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 2000; 20(7): 2470-2479
169. Klein TW, Cabral GA. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmun Pharmacol 2006; 1(1): 50-64.
170. Bidlack JM, Khimich M, Parkhill AL, Sumagin S, Sun B, Tipton CM. Opioid receptors and signaling on cells from the immune system. J Neuroimmun Pharmacol 2006; 1(3): 260-269
171. Börner C, Höllt V, Kraus J. Cannabinoid receptor type 2 agonists induce transcription of the mu-opioid receptor gene in Jurkat T cells. Mol Pharmacol 2006; 69(4): 1486-1491
172. Peterson PK, Gekker G, Hu S, Cabral G, Lokensgard JR. Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. J Neuroimmunol 2004; 147(1-2): 123-126
173. Rawls SM, Schroeder JA, Ding Z, Rodriguez T, Zaveri N. NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats. Neuropeptides 2007; 41(4): 239-247
174. Meunier JC. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur J Pharmacol 1997; 340(1): 1-15.
175. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 2006; 51(4): 773-781
176. Neu A, Földy C, Soltesz I. Postsynaptic origin of CB1-dependent tonic inhibition of GABA release at cholecystokinin-positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus. J Physiol 2007; 578(Pt 1): 233-247
177. Lafourcade CA, Alger BE. Distinctions among GABAA and GABAB responses revealed by calcium channel antagonists, cannabinoids, opioids, and synaptic plasticity in rat hippocampus. Psychopharmacology (Berl) 2008; 198(4): 539-549